Answers are grounded in this paper and cite their sources.
Perioperative blood loss remains a major challenge in older patients undergoing intramedullary nailing (IMN) for intertrochanteric fractures. Tranexamic acid (TXA) is increasingly used to reduce bleeding in orthopedic surgery. However, its efficacy and safety in this setting remain incompletely established. We searched PubMed, Web of Science, EMBASE, the Cochrane Library, and ClinicalTrials.gov from inception to March 30, 2026. Eligible randomized controlled trials (RCTs) compared TXA with control in patients undergoing IMN for intertrochanteric fractures. The primary outcome was transfusion requirement. Secondary outcomes included total blood loss (TBL), intraoperative blood loss (IBL), hidden blood loss (HBL), hemoglobin change, hematocrit change, transfused units per patient, thromboembolic complications, and mortality. Random-effects models were used for all meta-analyses. We also performed subgroup analyses, meta-regression, publication bias assessment, and certainty assessments using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Nineteen RCTs involving 1938 patients were included, with 990 in the TXA group and 948 in the control group. TXA significantly reduced transfusion requirement compared with control (risk ratio [RR] = 0.67, 95% confidence interval [CI]: 0.56–0.79, P < 0.001). Transfused units per patient were also significantly reduced (standardized mean difference [SMD] = − 0.28, 95% CI: − 0.48 to − 0.08, P = 0.006). TXA was also associated with significantly lower TBL (mean difference [MD] = − 282.09 mL, 95% CI: − 336.25 to − 227.92, P < 0.001), IBL (MD = − 32.56 mL, 95% CI: − 52.98 to − 12.13, P = 0.002), and HBL (MD = − 245.24 mL, 95% CI: − 302.58 to − 187.89, P < 0.001). TXA significantly attenuated postoperative hemoglobin decline (MD = 0.76 g/dL, 95% CI: 0.51–1.01, P < 0.001) and hematocrit decline (MD = 3.83% points, 95% CI: 1.76–5.90, P < 0.001). No significant differences were observed between the TXA and control groups regarding risk of deep venous thrombosis (RR = 1.19, P = 0.348), pulmonary embolism, myocardial infarction, cerebral infarction, or mortality. Subgroup analyses showed no significant differences by TXA administration route or dosing regimen. This meta-analysis supports TXA as an effective perioperative blood management strategy for patients undergoing IMN for intertrochanteric fractures. TXA was associated with reduced transfusion requirement and perioperative blood loss, with no statistically significant increase detected in the risk of thromboembolic complications or mortality. However, most included studies were conducted in China and evidence certainty was low or very low for most outcomes, warranting cautious interpretation.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: